GlassScriptPhysician profile
Terri H Ginther
NPI 1447436175
$4,633.19
in general payments reported to CMS, 2019-2025
23 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $852 · 2023: $796 · 2024: $1,013 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.55 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $666.36 | 2021-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $496.66 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $484.88 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $482.41 | 2022-2025 | Tarpeyo |
| Amgen INC. | $357.20 | 2021-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $344.66 | 2022-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $331.04 | 2022-2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $302.68 | 2021-2025 | Rayaldee |
| Ardelyx, INC. | $269.06 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.03 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $156.84 | 2021-2023 | Lupkynis |
| Akebia Therapeutics INC | $106.14 | 2023-2024 | Auryxia, Vafseo |
| Alexion Pharmaceuticals, INC. | $104.16 | 2021-2023 | Soliris |
| Travere Therapeutics, INC. | $68.65 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $55.52 | 2022-2024 | Terlivaz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $35.66 | 2022-2023 | Velphoro |
| Daiichi Sankyo INC. | $34.89 | 2022 | |
| Glaxosmithkline, LLC. | $33.45 | 2022 | |
| Lilly USA, LLC | $32.35 | 2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $31.52 | 2024 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $25.85 | 2025 | Venxxiva |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2021 | |
| Medtronic, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Ginther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.